Skip to main content
TipRanks
Go Ultimate75% OFF

Fate Therapeutics (F6T) Q1 2024 Earnings Report

1 Followers

DE:F6T Q1 2024 EPS Results

Actual EPS
-EUR 0.43
Consensus EPS
-EUR 0.43
Beat/Miss
Beat by +EUR 0.00
One Year Ago EPS
-EUR 0.17

DE:F6T Q1 2024 Revenue Results

Actual Revenue
EUR 1.75M
Expected Revenue
EUR 1.51M
Beat/Miss
Beat by +EUR 241.51K
YoY Revenue Growth
-96.74%

Earnings Announcement Details

Quarter
Q1 2024
Date
05/09/2024
Time
After Close
Conference Call
Thursday, May 9, 2024
DE:F6T Upcoming Earnings

Fate Therapeutics's next earnings date is estimated for March 1, 2027, based on past reporting schedules.

Q1 2024 Earnings Call Audio

DE:F6T Q1 2024 Earnings Call
0:00 / 0:00

Q1 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q1 2024 Earnings Call Summary

Q1 2024
Earnings Call Date:May 09, 2024|% Change Since:-72.23%|
Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.

Company Guidance

During the Fate Therapeutics Q1 2024 earnings call, the company provided guidance on its clinical and financial outlook. Key program initiatives were discussed, including the FT819 CAR T-cell and FT522 CAR NK cell programs, with notable translational data presented at the American Society of Gene and Cell Therapy Annual Meeting. The company highlighted its plans to achieve several clinical milestones across its iPSC product pipeline, targeting both cancer and autoimmune diseases. Financially, Fate Therapeutics raised $100 million through an underwritten offering and private placement, ending the first quarter with approximately $391 million in cash. Operating expenses for the full year are projected between $215 million and $230 million, with a year-end cash balance exceeding $270 million. The company's strategic focus is on demonstrating the disease-modifying potential of its therapies while maintaining a strong financial position to support ongoing and future clinical development.

  • FT819 and FT522 Data PresentationPresented promising data from FT819 and FT522 programs at the ASGCT Annual Meeting, showing potential disease-modifying effects and immune reset in B-cell-mediated autoimmune diseases.
  • First Lupus Patient TreatedThe first lupus patient was treated with FT819, showing no notable adverse events post-treatment.
  • Strong Financial Position and FundraisingRaised $100 million through an underwritten offering and a private placement, ending the quarter with $391 million in cash, cash equivalents, and investments.
  • FT522 Safety AssessmentFirst 3 patients in FT522 study completed safety assessment without dose-limiting toxicities.

DE:F6T Earnings History

DE:F6T earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 01, 20272026 (Q4)-0.23--0.25――
Nov 05, 20262026 (Q3)-0.25-0.23-0.257.41% (+0.02)
Aug 13, 20262026 (Q2)-0.24-0.23-0.2613.79% (+0.04)
May 13, 20262026 (Q1)-0.26-0.24-0.2918.75% (+0.05)
Feb 26, 20262025 (Q4)-0.25-0.25-0.438.64% (+0.15)
Nov 13, 20252025 (Q3)-0.27-0.25-0.3632.50% (+0.12)
Aug 12, 20252025 (Q2)-0.32-0.26-0.312.12% (+0.04)
May 13, 20252025 (Q1)-0.35-0.29-0.4331.91% (+0.14)
Mar 05, 20252024 (Q4)-0.39-0.40-0.412.22% (+0.01)
Nov 12, 20242024 (Q3)-0.38-0.36-0.4213.04% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed